Definium Therapeutics (MMQ0) Stock Forecast & Price Target
MMQ0 Analyst Ratings
Strong Buy
16Buy0Hold0Sell
Based on 16 analysts giving stock ratings to Definium Therapeutics in the past 3 months
MMQ0 Stock 12 Month Forecast
Average Price Target
EUR 65.12▲(100.38% Upside)Based on 16 Wall Street analysts offering 12 month price targets for Definium Therapeutics in the last 3 months. The average price target is EUR 65.12 with a high forecast of EUR 81.46 and a low forecast of EUR 47.44. The average price target represents a 100.38% change from the last price of EUR 32.50.
Past 12 Months12 Month ForecastDec2025Sep2026
HighEUR 81.46
AverageEUR 65.12
LowEUR 47.44
Highest Price TargetHighestEUR 81.46Average Price TargetEUR 65.12Lowest Price TargetLowestEUR 47.44
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | EUR 59.08 | buy | 81.78%Upside | Reiterated | 10/19/26 | ||
| Tessa Romero | J.P. Morgan | EUR 75.19 | buy | 131.36%Upside | Initiated | 10/09/26 | ||
| Tazeen Ahmad | Bank of America Securities | EUR 81.46 | buy | 150.64%Upside | Reiterated | 10/07/26 | ||
| Francois Brisebois | LifeSci Capital | EUR 69.82 | buy | 114.84%Upside | Reiterated | 09/19/26 | ||
| Patrick Trucchio | H.C. Wainwright | EUR 62.66 | buy | 92.80%Upside | Reiterated | 09/15/26 | ||
| Christopher Chen | Robert W. Baird | EUR 67.14→EUR 70.72 | buy | 117.59%Upside | Reiterated | 09/15/26 | ||
| Sumant Kulkarni | Canaccord Genuity | EUR 57.29→EUR 69.82 | buy | 114.84%Upside | Reiterated | 09/15/26 | ||
| Justin Walsh | JonesTrading | EUR 80.56 | buy | 147.89%Upside | Reiterated | 09/15/26 | ||
| Paul Matteis | Stifel Nicolaus | EUR 53.71→EUR 59.98 | buy | 84.54%Upside | Reiterated | 09/15/26 | ||
| Michael Okunewitch | Maxim Group | EUR 49.23 | buy | 51.49%Upside | Reiterated | 09/15/26 | ||
| Ami Fadia | Needham | EUR 59.08 | buy | 81.78%Upside | Reiterated | 09/14/26 | ||
| Jay Olson | Oppenheimer | EUR 62.66→EUR 67.14 | buy | 106.57%Upside | Reiterated | 09/14/26 | ||
| Benjamin Burnett | Wells Fargo | EUR 64.45 | buy | 98.31%Upside | Reiterated | 08/31/26 | ||
| David Amsellem | Piper Sandler | EUR 67.14 | buy | 106.57%Upside | Reiterated | 08/17/26 | ||
| Andrew Tsai | Jefferies | EUR 58.18 | buy | 79.03%Upside | Reiterated | 08/13/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Brian Abrahams | 10/19/26 | EUR 59.08 | buy | 81.78%Upside | Reiterated | RBC Capital | ||
| Tessa Romero | 10/09/26 | EUR 75.19 | buy | 131.36%Upside | Initiated | J.P. Morgan | ||
| Tazeen Ahmad | 10/07/26 | EUR 81.46 | buy | 150.64%Upside | Reiterated | Bank of America Securities | ||
| Francois Brisebois | 09/19/26 | EUR 69.82 | buy | 114.84%Upside | Reiterated | LifeSci Capital | ||
| Patrick Trucchio | 09/15/26 | EUR 62.66 | buy | 92.80%Upside | Reiterated | H.C. Wainwright | ||
| Christopher Chen | 09/15/26 | EUR 67.14→EUR 70.72 | buy | 117.59%Upside | Reiterated | Robert W. Baird | ||
| Sumant Kulkarni | 09/15/26 | EUR 57.29→EUR 69.82 | buy | 114.84%Upside | Reiterated | Canaccord Genuity | ||
| Justin Walsh | 09/15/26 | EUR 80.56 | buy | 147.89%Upside | Reiterated | JonesTrading | ||
| Paul Matteis | 09/15/26 | EUR 53.71→EUR 59.98 | buy | 84.54%Upside | Reiterated | Stifel Nicolaus | ||
| Michael Okunewitch | 09/15/26 | EUR 49.23 | buy | 51.49%Upside | Reiterated | Maxim Group | ||
| Ami Fadia | 09/14/26 | EUR 59.08 | buy | 81.78%Upside | Reiterated | Needham | ||
| Jay Olson | 09/14/26 | EUR 62.66→EUR 67.14 | buy | 106.57%Upside | Reiterated | Oppenheimer | ||
| Benjamin Burnett | 08/31/26 | EUR 64.45 | buy | 98.31%Upside | Reiterated | Wells Fargo | ||
| David Amsellem | 08/17/26 | EUR 67.14 | buy | 106.57%Upside | Reiterated | Piper Sandler | ||
| Andrew Tsai | 08/13/26 | EUR 58.18 | buy | 79.03%Upside | Reiterated | Jefferies |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Definium Therapeutics
3 Months
Success Rate7/9 ratings generated profit
78%
Average Return
+36.34%
Copying Ami Fadia's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +36.34% per trade.
1 Year
Success Rate13/16 ratings generated profit
81%
Average Return
+123.71%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +123.71% per trade.
2 Years
Success Rate13/15 ratings generated profit
87%
Average Return
+186.91%
Copying Sumant Kulkarni's trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +186.91% per trade.
MMQ0 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 36 | 22 | 23 | 27 | 28 |
| Buy | 11 | 9 | 20 | 14 | 12 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 47 | 31 | 43 | 41 | 40 |
In the current month, MMQ0 has received 40 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MMQ0 average Analyst price target in the past 3 months is 65.12.
MMQ0 Financial Forecast
HighEUR -0.40
ConsensusEUR -0.50
LowEUR -0.63
MMQ0 Earnings Forecast
Next quarter’s earnings estimate for MMQ0 is -EUR 0.50 with a range of -EUR 0.63 to -EUR 0.40. The previous quarter’s EPS was -EUR 1.29. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 0.00
ConsensusEUR 0.00
LowEUR 0.00
MMQ0 Sales Forecast
Next quarter’s sales forecast for MMQ0 is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
MMQ0 Stock Forecast FAQ
What is DE:MMQ0’s average 12-month price target, according to analysts?
Based on analyst ratings, Definium Therapeutics’s 12-month average price target is €65.12.
What is DE:MMQ0’s upside potential, based on the analysts’ average price target?
Definium Therapeutics has 100.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Definium Therapeutics a Buy, Sell or Hold?
Definium Therapeutics has a consensus rating of Strong Buy, which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
What is Definium Therapeutics’s share price target?
The average share price target for Definium Therapeutics is €65.12. This is based on 16 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €81.46, and the lowest forecast is €47.44. The average share price target represents a 100.38% increase from the current price of €32.5.
What do analysts say about Definium Therapeutics?
Definium Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Street analysts.
How can I buy shares of Definium Therapeutics?
To buy shares of DE:MMQ0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
